Amneal Pharmaceuticals logo

Amneal Pharmaceuticals

AMRX | NASDAQ
Chart Builder DCF Calculator
$21.23
-$0.15 (-0.70%)
At close: Nov 16, 2026, 4:00 PM ET
$21.01
-$0.22 (-1.04%)
After-hours: Nov 16, 2026, 7:55 PM ET
-0.70%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
51.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #243/1021 (Top 24%)

Key Statistics

Market Data

Market Cap $7.4B
1D Range
21.10 21.60
52W Range
11.52 21.71

Valuation (TTM)

PE 50.55
PB 13.92
EV/EBITDA 13.76

Valuation (NTM)

Forward PE 20.17
Forward PEG 1.53
Price Target $24.00
Loading financial charts...

Profile

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and ...

Sector Healthcare
Employees 8,700
IPO Date May 7, 2018
Fiscal Year January - December

Latest News

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised

13 days ago · zacks.com

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

14 days ago · marketbeat.com

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

14 days ago · zacks.com

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

14 days ago · zacks.com

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal Reports Third Quarter 2026 Financial Results

14 days ago · globenewswire.com

Amneal Reports Third Quarter 2026 Financial Results
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

21 days ago · zacks.com

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

21 days ago · zacks.com

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options

21 days ago · zacks.com

Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

22 days ago · zacks.com

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.26
Beat +9.52%
REV
$862.68M
Beat +5.49%
Next Earnings
Feb 26, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$24.00
Upside
+13.05%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.